Mark Hofmeyer
3 Papers
22 Citations
Mark Hofmeyer is an academic researcher. The author has contributed to research in topics: Clinical endpoint & Heart failure. The author has an hindex of 2, co-authored 3 publications.
Chat about Author
Papers
Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study
Filipa Lynce,Ana Barac,X. Geng,Chau T. Dang,Anthony F. Yu,Anthony F. Yu,Karen L. Smith,Christopher Gallagher,Paula R. Pohlmann,Raquel Nunes,P. Herbolsheimer,Robert D. Warren,Monvadi B. Srichai,Mark Hofmeyer,A. Cunningham,P. Timothee,Federico M. Asch,Ayesha N. Shajahan-Haq,Ming Tony Tan,Claudine Isaacs,Sandra M. Swain +20 more
TL;DR: This study provides safety data of HER2-targeted therapies in patients with breast cancer and reduced LVEF while receiving cardioprotective medications and close cardiac monitoring and demonstrates the importance of collaboration between cardiology and oncology providers to allow for delivery of optimal oncologic care.
Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart function.
Katia E. Khoury,Katia E. Khoury,Filipa Lynce,Filipa Lynce,Ana Barac,Xue Geng,Chau T. Dang,Anthony F. Yu,Karen L. Smith,Christopher Gallagher,Paula R. Pohlmann,Raquel Nunes,P. Herbolsheimer,Robert D. Warren,Monvadi B. Srichai,Mark Hofmeyer,Federico M. Asch,Ming Tan,Claudine Isaacs,Claudine Isaacs,Sandra M. Swain,Sandra M. Swain +21 more
TL;DR: The SAFE-HEaRt trial as mentioned in this paper was designed to evaluate the safety of HER2-targeted therapy for breast cancer patients with compromised heart function at a median follow-up of 3.5 years.
22
SAFE-HEaRt: A pilot study assessing the cardiac safety of HER2 targeted therapy in patients with HER2 positive breast cancer and reduced left ventricular function.
Filipa Lynce,Ana Barac,Xue Geng,Chau T. Dang,Anthony F. Yu,Karen L. Smith,Christopher Gallagher,Paula R. Pohlmann,Raquel Nunes,P. Herbolsheimer,Robert D. Warren,M. Barbara Srichai,Mark Hofmeyer,Andrecia Cunningham,Patricia Timothee,Federico M. Asch,Ayesha N. Shajahan-Haq,Ming Tony Tan,Claudine Isaacs,Sandra M. Swain +19 more
TL;DR: Safe and effective HER2 targeted therapies have substantially improved the prognosis of patients with BC however they can be associated with cardiac toxicity, and SAFE-HEaRt is the first investigator-initiation drug for this indication.
7